fbpx Opioid Agonist Therapy (OAT) and lower risk of multiple causes of death | NDARC - National Drug and Alcohol Research Centre

Opioid Agonist Therapy (OAT) and lower risk of multiple causes of death

Image - Opioid Agonist Therapy (OAT) and lower risk of multiple causes of death
Date Published:
8 Jul 2021
Contact person:
NDARC.events@unsw.edu.au
Event date: 
Thursday, 8 July 2021 - 3:00pm

This webinar will share findings from a systematic review that examined mortality and causes of death among people with opioid dependence.

Mortality among people with opioid dependence is much higher than that of the general population. Opioid agonist treatment (OAT), which includes methadone and buprenorphine treatment, is an effective treatment for opioid dependence. We examined mortality rates by time during and out of OAT, by cause of death, study methodology, participant characteristics, and setting.

About the speaker

Tom Santo Jr is a PhD Candidate at NDARC, UNSW Sydney. He completed his Master of Public Health and began working at NDARC in 2018. Tom’s research interests include prevention and treatment of both pharmaceutical and opioid use disorder (OUD). The focus of his PhD is the relationship between childhood maltreatment, mental disorders and OUD among people who use opioids.

Location: 
This is an online event. You will be emailed the link when you register.
Cost: 
Free
Booking deadline: 
Thursday, 8 July 2021 - 3pm
Contact for inquiries: 
NDARC.events@unsw.edu.au